IL6 and neoplasm: In summary, we establish an intravenous xenograft model for DLBCL that shortens the time to tumor development (median survival of U2932-Luc and VAL-Luc in NSG-IL6 mice; 49 days and 24 days), shows highly uniform tumor progression, follows a clinical progression of the disease, and requires minimal genetic alterations in mice with high potential to advance the preclinical testing of new therapeutics.